The progress on sensitivity of PARPi and platinum in mCRPC with DNA damage repair gene mutation / 中华泌尿外科杂志

ABSTRACT

DNA damage repair (DDR) defects occurred in 8%-16% of metastatic castration resistant prostate cancer (mCRPC). DDR gene mutation was related to poorer prognosis. Patients with DDR gene mutation, especially BRCA1/2 mutation, showed high sensitivity to poly ADP-ribose polymerase inhibitor (PARPi) and platinum.